Abbott Molecular, Abbott Park, Ill, has introduced a new capability for its RealTime m2000 system to enhance the system’s flexibility and make molecular testing easier and more efficient for laboratories.
The new mPlus makes it possible for labs of any size to perform molecular diagnostic tests for infectious disease detection and therapy-monitoring.
Its capability is currently available for Abbott’s RealTime HIV, HCV, HBV, CT/NG, and CT assays outside the United States, and for the RealTime CT/NG assay within the United States.
mPlus allows labs to process samples when they are ready rather than holding for larger batch runs – providing faster results to physicians and patients. Its capability also optimizes reagent use, reduces laboratory cost of operations, and offers a new automatic inventory feature to improve system ease-of-use.
[Source: Abbott]
